Stone X Group Inc. Cue Biopharma, Inc. Transaction History
Stone X Group Inc.
- $1.58 Billion
- Q1 2025
A detailed history of Stone X Group Inc. transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Stone X Group Inc. holds 14,058 shares of CUE stock, worth $9,559. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,058Holding current value
$9,559% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CUE
# of Institutions
52Shares Held
11.5MCall Options Held
10.1KPut Options Held
1.4K-
Bleichroeder LP New York, NY5MShares$3.4 Million1.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.32MShares$1.57 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$514,5800.0% of portfolio
-
Geode Capital Management, LLC Boston, MA694KShares$471,8450.0% of portfolio
-
Robertson Stephens Wealth Management, LLC San Francisco, CA479KShares$325,3800.02% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $24.1M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...